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ABSTRACT
Several recent publications have drawn attention to the role of the
thyroid hormone status of the mother on the future neuropsycholog-
ical development of the child. The screening of pregnant women for
clinical or subclinical hypothyroidism based on second trimester el-
evated maternal TSH values has been proposed. Here, we have sum-
marized present epidemiological and experimental evidence strongly
suggesting that conditions resulting in first trimester hypothyrox-
inemia (a low for gestational age circulating maternal free T4,
whether or not TSH is increased) pose an increased risk for poor
neuropsychological development of the fetus. This would be a conse-
quence of decreased availability of maternal T4 to the developing
brain, its only source of thyroid hormone during the first trimester;
T4 is the required substrate for the ontogenically regulated generation
of T3 in the amounts needed for optimal development in different
brain structures, both temporally and spatially. Normal maternal T3
concentrations do not seem to prevent the potential damage of a low
supply of T4, although they might prevent an increase in circulating
TSH and detection of the hypothyroxinemia if only TSH is measured.
Hypothyroxinemia seems to be much more frequent in pregnant
women than either clinical or subclinical hypothyroidism and auto-
immune thyroid disease, especially in regions where the iodine intake
of the pregnant woman is inadequate to meet her increased needs for
T4. It is proposed that the screening of pregnant women for thyroid
disorders should include the determination of free T4 as soon as
possible during the first trimester as a major test, because hypothy-
roxinemia has been related to poor developmental outcome, irrespec-
tive of the presence of high titers of thyroid autoantibodies or elevated
serum TSH. The frequency with which this may occur is probably 150
times or more that of congenital hypothyroidism, for which successful
screening programs have been instituted in many countries. (J Clin
Endocrinol Metab 85: 3975–3987, 2000)
THE RECENT PUBLICATION by Haddow et al. (1) on“Maternal thyroid deficiency during pregnancy and
subsequent neuropsychological development of the child,”
has drawn new attention to the relationship between ma-
ternal thyroid deficiencies and the future neuropsychological
development of her child. This is a very important issue that
has, unfortunately, been somewhat misunderstood for dec-
ades, to the point that Mestman (2) unexpectedly found that
in a recent study from Los Angeles involving 78 women who
were hypothyroid at booking into the clinic, 34 (44%) had
discontinued thyroid therapy at the time they discovered
they were pregnant “some after receiving advice from their
own health care professionals, and others because of concern
for the potential harmful effect of thyroid medications on the
conceptus.”
As a consequence of the report by Haddow et al. (1) and
other (3) recent studies, the possibility of avoiding potentially
preventable alterations of neuropsychological development
by screening pregnant women for maternal thyroid hormone
deficiencies is being discussed. Even before this new evi-
dence was presented relating maternal thyroid status with
mental development of the child, screening for thyroid dis-
functions during pregnancy had already been advocated
because of their frequency and risk for the mother’s health
and for the outcome of pregnancy (4).
Because such programs are not easily implemented, we
believe the present comments may be pertinent to obtain the
maximum benefits for the largest number of children.
Maternal thyroid hormone deficiencies and fetal
neurodevelopment
Aim. Our aim is to clarify whether the principal factor leading
to poorer neurodevelopment of the child is: 1) maternal hy-
pothyroidism, whether clinical or subclinical, as defined by
TSH higher than the 98th percentile of the normal population
(1); or 2) maternal hypothyroxinemia per se, whether or not
TSH is increased (3).
We will review, albeit in very condensed form, relevant
information obtained from epidemiological, clinical, and ba-
sic science studies that strongly suggest that maternal thy-
roid status, especially in early pregnancy, is causally related
to the survival and neuropsychological development of the
offspring.
Reports from human populations with severe iodine deficiency
(ID). After prolonged observations of cretins born in areas
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with endemic goiter, an important role of maternal thyroid
function was suspected “it is of the greatest importance to
inquire into the ante-natal history of all backward children
and to examine the mother for thyroid defect” (5).
Not until 1965, however, were data presented that sug-
gested that the inability of the mothers to increase their low
circulating T4 during pregnancy was causally related to the
birth of cretins (6). Thereafter, numerous groups (see Table
1) presented convincing evidence that maternal hypothyrox-
inemia early in pregnancy is not only the cause of repro-
ductive failure and the birth of neurological cretins, but also
of less severe mental deficits that affect a large proportion of
the apparently “normal” (noncretin) population of the same
area. These deficits, as well as the birth of cretins, are irre-
versible consequences of the ID and can only be prevented
within the first months of gestation with an adequate supply
of iodine. This finding is in conceptual agreement with the
very early (first trimester) development of cerebral structures
that are characteristically affected in neurological cretinism.
Two other findings are quite important in the present con-
text: namely, that the motor and cognitive impairment of the
progeny was correlated with the degree of maternal hypo-
thyroxinemia, and not with circulating T3 or TSH levels; and
that these hypothyroxinemic women are not clinically hy-
pothyroid, because of their relatively normal circulating T3.
Reports from human populations without severe ID. Table 2 sum-
marizes relevant information from studies carried out in
areas without severe ID, which have suggested an important
role of maternal T4 in the outcome of the pregnancy and in
the neuropsychological development of the progeny, and
which have provided increasing evidence that is the critical
factor is maternal hypothyroxinemia early in gestation.
The concept of “hypothyroxinemia” of the pregnant
woman was defined by Man and et al. (18–21) as a circulating
level of T4 [then measured as butanol extractable iodine
(BEI)], below the normal range for women in the same tri-
mester of pregnancy, whether or not “clinical hypothyroid-
ism” was evident. These pioneering studies not only drew
attention to the decreased mental development of the prog-
eny of hypothyroxinemic women but also reported that this
negative effect was prevented by adequate and early cor-
rection of the maternal hypothyroxinemia with thyroid
preparations.
Table 2 also includes reports regarding the increased pro-
portion of unsuccessful or complicated pregnancies in hy-
pothyroxinemic women (i.e. spontaneous abortions, prema-
ture births, major complications at delivery, perinatal deaths,
congenital malformations) and their relation to first trimester
low free T4 (FT4), but not to FT4 near term; early treatment
to prevent such complications has been stressed (22).
During the last decade, Pop et al. (23) have drawn attention
to an average impairment of 10.5 IQ points in the offspring
of mothers with high thyroid peroxidase antibody (TPO-Ab)
titers during pregnancy. They have later reported (3) that in
normal pregnancies a maternal FT4, at 12 weeks of gestation,
which is equal to or less than the 10th percentile of first
trimester values (10.4 pmol/L in their series), is associated
with distinctly impaired psychomotor infant development at
the age of 10 months, whether or not TSH and TPO-Abs were
elevated. They have confirmed this is an ongoing prospective
study (24), comparing developmental indices, determined at
3 weeks and 1 and 2 yr of age, with maternal FT4. Smit et al.
(25) have found a similar relationship between first trimester
FT4 and the early neurodevelopment of children born from
treated hypothyroid women. These studies (3, 25) did not
find significant correlations when the neurodevelopmental
outcome was related to maternal TSH, or to FT4 later in
gestation.
The finding that FT4 levels after midgestation are not cor-
related with the developmental outcome does not mean that
TABLE 1. Brief description of some major pioneering findings from studies in areas with severe ID
Major findings Year Main references Based on
Suggest maternal thyroid defects when
the child is mentally retarded.
1915
1917
Switzerland (7)
Himalayas (5)
Extensive clinical observations in
areas with severe ID.
Neurological cretinism is related to the
low circulating T4 of pregnant
women who are not clinically
hypothyroid.
1965 Papua, New Guinea (6) PBI was used as measure of T4.
The birth of cretins is prevented by
iodization of pregnant women before
pregnancy, or very soon after its
onset.
1971 Papua, New Guinea (8) Controlled double-blind
epidemiological study.
Neurodevelopment of the noncretin
population is also affected and only
prevented by iodization before
midgestation.
1974 Peru´ (9, 10), China (11) Controlled iodization program with
measurements of maternal serum
PBI, T4 or FT4, and IQ of progeny.
Neurodevelopment of the noncretinous
progeny is significantly correlated to
maternal T4, but not to T3 or TSH.
1976 Papua, New Guinea (12–15) Determinations of maternal T4, FT4,
T3 and TSH, and psychometric
testing of progeny.
Low maternal T4 is causally related to
“reproductive failure.”
1980 Review (16) Described for women with
hypothyroidism and for women
from ID areas.
Brain structures, that are severely
affected in neurological cretinism,
develop before midgestation.
1989 Review (17) Neurological examination of cretins
from ID regions in different
continents.
PBI, Protein-bound iodine, mainly I in the form of T4; reproductive failure, increased proportions of spontaneous abortions, premature births,
major complications at delivery, perinatal death, and congenital malformations.
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after midgestation the protective effect of maternal T4 has
been lost, or that the fetal brain no longer requires thyroid
hormone. Prompt postnatal treatment of athyrotic babies
prevents the severe mental retardation that was associated
with this condition when onset of treatment was delayed
(30). This very positive result of Neonatal Screening Pro-
grams has been quoted as argument that the human fetal
brain does not require thyroid hormone for normal devel-
opment before birth (31). But, an alternative explanation is
that the fetal brain has been protected by the normal thyroid
status of their mothers. Indeed, when maternal thyroid status
is not normal throughout gestation and fetal thyroid function
is also impaired, neurological damage and mental retarda-
tion of the child can be as severe as in neurological cretinism,
despite immediate postnatal treatment of the baby with T4
(17, 32–35).
Reports of poor developmental outcome in many babies
faced with a premature interruption of the maternal supply
of thyroid hormone—occurring when their thyroid is still
quite immature (36)—also indicate that the fetal brain needs
thyroid hormone throughout gestation and that a normal
supply of maternal T4 has an important protective role after
midgestation. The data from two such studies (37, 38) show
a direct relationship between the degree of neonatal hypo-
thyroxinemia and future neurodevelopment of the progeny.
Both neurological dysfunction at 5 yr of age and school
failure at 9 yr of age were significantly related to lower T4
levels during the neonatal period (37). Even after correction
for other perinatal confounding factors, there was a statis-
tically significant 30% increase in the odds of neurological
dysfunction and school failure for each decrease of the T4
level by 1 sd. In the second study (38), the odds ratio for
increased cerebral palsy in preterm infants with neonatal
hypothyroxinemia increased more than 4-fold (after correc-
tion for many possible confounding factors), with a mean
reduction of 7 points in the mental developmental score at 2
yr of age. The postnatal FT4 of premature babies, lower than
that of fetuses of comparable age still in utero, is usually not
accompanied by an elevation of circulating TSH (39), and a
correlation is not found between neurodevelopmental out-
come and neonatal TSH levels. Thus, in these babies, the
critical factor for the prediction of future neurodevelopmen-
tal problems is the degree of their neonatal hypothyroxine-
mia, and not hypothyroidism, as detected by elevated cir-
culating TSH. The degree of the hypothyroxinemia not only
depends on gestational age and immaturity of the thyroid
gland of the newborn, but is also increased by a low iodine
intake (40). There is, however, no information regarding a
possible relationship with the thyroxinemia of their mothers
up to birth, but it seems plausible that maternal hypothy-
roxinemia, especially when related to ID, would only in-
crease the difficulties encountered by the newborn in meet-
ing postnatal hormone requirements, including those of the
developing brain.
Information from basic research. The possible protective role of
the maternal transfer of thyroid hormone to the fetus was
actually not actively disputed until the mid-1960s and early
1970s (41–43). However, during the following decades the
general consensus became that the placenta is virtually im-
permeable to the iodothyronines and that the small amounts
possibly transferred would be of no physiological impor-
tance, either in health or disease, ideas that were supported
by experiments involving sheep. The prevailing idea that
there is no biologically significant transfer of thyroid hor-
mones throughout gestation (including the first trimester)
and that these hormones would not be required for normal
early (or late) fetal brain development is likely to have con-
tributed to a general lack of understanding and acceptance
of the results from the epidemiological and clinical studies
summarized in Tables 1 and 2. A convincing explanation
could not be proposed for the relation between early (mostly
first trimester) maternal hypothyroxinemia and poor neu-
rodevelopmental outcome of the child. It was difficult to
reconcile the very severe, and mostly irreversible, neurolog-
ical damage of cretins (with normal thyroid function when
iodine is supplied), with the successful prevention of severe
brain damage by early postnatal treatment of congenital
hypothyroidism (CH) babies, including athyrotics. The lack
of protective effects of maternal T3, compared with T4, ob-
TABLE 2. Major findings from studies in areas without known ID
Major findings Year Main references Based on
“Reproductive failure”a of hypothyroid
women.
1962 U.S.A. (20, 26, 27), Belgium (4) Maternal BEI, T4, FT4, TSH.
Reproductive failure related to 1st
trimester low FT4.
1995 U.S.A. (22) FT4, TSH.
Maternal “hypothyroxinemia” is related
to low IQ of progeny; both corrected by
treatment (during pregnancy).
1967 U.S.A. (18–21, 28, 29) IQ of the progeny at 7 yr of age,
compared with maternal BEI,
with and without treatment.
Maternal thyroid anti-TPO antibodies
during pregnancy related to lower IQ
of progeny.
1995 The Netherlands (23) IQ of progeny, maternal T4, FT4,
TSH, anti-TPO.
Psychomotor development is correlated
to 1st trimester FT4 #10th percentile,
not to TSH, anti-TPO, or 3rd trimester
FT4.
1999 The Netherlands (3, 24) Psychomotor and mental
development at 3 weeks to 2 yr
of age, FT4, TSH, anti-TPO.
Increased risk of poor neuropsychological
scores in progeny of women with
maternal TSH $98th percentile.
1999 U.S.A. (1) IQ scores of progeny of women with
2nd trimester maternal TSH
$98th percentile.
a Increased proportions of spontaneous abortions, premature births, major complications at delivery, perinatal death, and congenital
malformations.
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served in areas with severe ID, also posed many unanswered
questions.
New findings, mostly obtained during the last 15 yr in
experimental animals and in man, now clearly point to a role
for the maternal transfer of thyroid hormone in brain de-
velopment throughout fetal life and offer plausible expla-
nations to the above questions. Despite these new findings
and despite increasing acceptance of an important role for
maternal T4 in the prevention of severe brain damage in cases
of CH, it is still stated that “Whether thyroid hormone is
needed during the 1st trimester is less certain. If it is, it must
be supplied by the mother, because none is secreted by the
fetus until the middle trimester” (44). Because this point is
essential for an understanding of the possible importance of
first trimester FT4 in fetal neurodevelopment, we will briefly
review in Table 3 much of the information now available for
experimental animals and for man.
Information obtained in experimental animals
Before onset of fetal thyroid function (FTF). Both T4 and T3 are
available to early embryos, with very low concentrations
being found when circulating concentrations in the mother
are low. When this occurs, prenatal and postnatal develop-
mental alterations can be shown. Nuclear receptors for T3
(TRs) are also found in the early fetal brain, partially occu-
pied by T3, in rats, chicken, and sheep, with concentrations
increasing during periods of very active cortical neurogen-
esis. Many cerebral genes sensitive to thyroid hormone de-
privation have been identified, mostly in postnatal rats (45,
46), during a phase of brain development that corresponds
to the second half of gestation and early postnatal period in
man. The few studies reporting biological effects in the fetal
rat brain at a phase of development corresponding to the first
half of pregnancy in man have been restricted to a period
coinciding or following onset of FTF at 17.5–18. days of
gestation [E17.5-E18 (47–49)]. There is, however, increasing
evidence that maternal thyroid hormone is already needed
before onset of FTF; maternal hypothyroidism, as induced by
treatment with goitrogens or thyroidectomy, interferes with
the normal proliferation of some neurons usually completed
by E12 (50). It also affects the migration of cells proliferating
at E14-E15, normally reaching layer VI of the cortex by E16-
E17 (51), and the cortical expression of several genes by E16
(52). Directly related to the possible role of maternal hypo-
thyroxinemia without hypothyroidism is our very recent
finding that an altered early migration of cortical cells can be
observed in offspring of rats with severe ID (53). These dams
have very low circulating T4, but circulating T3 is high
enough to prevent “clinical” hypothyroidism.
After onset of FTF. The maternal to fetal transfer of thyroid
hormone is not interrupted and continues to contribute to the
thyroid hormone available to fetal tissues at term. Of special
interest in the present context is the finding that a normal
level of maternal T4 is sufficient to protect a hypothyroid
fetus preferentially from cerebral T3 deficiency until birth. It
is important to realize that maternal T4 and T3 are not equiv-
alent with regard to this preferential protection of the hy-
pothyroid fetal brain from T3 deficiency. Without correction
of the low maternal T4, normal levels of T3 in the maternal
or fetal circulation have no protective effect because during
fetal and postnatal development cerebral structures of the rat
depend entirely on the local generation of T3 from T4 by type
II 59-iodothyronine deiodinase (D2), the activity of which is
inversely related to the availability of T4. Changes in the
activity of 5-iodothyronine deiodinase (D3), which inacti-
vates both T3 and T4, also play a role. During these periods
TABLE 3. Major findings from studies performed with experimental animals, and their possible relevance for man
Experimental animals Man
Before onset of FTF
T4 and T3 present in embryonic and
fetal fluids and tissues.
Rat (77–79), chicken (80), salmon (81),
sheep (73)
Shown (82–84).
T4 and T3 are of maternal origin. Rat (85), chicken (80), salmon (81) Supported by correlation of T4 in
extra-embryonic cavity with
maternal serum T4 (83).
Nuclear receptors for T3 are found, and
partly occupied by T3.
Rat (86–90), chicken (91, 92) and
sheep (72)
Shown (93–95).
D2 and D3 are expressed in brain. Rat (96), chicken (97) Shown (98).
Adverse cerebral effects of low maternal
T4 early in pregnancy are being
reported.
Rat (50–53), sheep (68). Reviews
(85, 99, 100)
Supported by epidemiological and
clinical studies (Table 1), and an
in vitro study (101).
Between onset of FTF and birth
Maternal transfer continues and
contributes to fetal extrathyroidal
thyroid hormone pools.
Rat (102–104) Strongly suggested by earlier studies
(42, 105–109). Shown by Vulsma et
al. (110).
Brain T3 is highly dependent on T4 and
the activities of D2 and D3, not on
systemic T3.
Rat (74–76, 96, 102, 103, 111–113) Continuing role of T4-regulated D2,
and D3, in cerebral T3 (114).
Normal maternal levels of T4 protect
the fetal brain from T3 deficiency.
Rat (102, 103) Supported by good results of early
treatment with T4 of newborns
with CH, born from mothers with
normal T4.
Normal T3 in hypothyroxinemic mother
neither prevents cerebral T3
deficiency, nor maintains T3
homeostasis.
Rat (74–76, 102, 103, 113) Supported by findings in ID cretins,
whose mothers have low T4, but
normal circulating T3 (Table 1).
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of development, the contribution of systemic T3 to the
amount of T3 in fetal cerebral structures is negligible. Fetal
brain T3 levels are also protected from excessive maternal
circulating T4, whereas cerebral T3 homeostasis is not en-
sured when maternal circulating T3 is excessive. Such results
suggest that over-treatment of the mother with T4 is poten-
tially less damaging for the fetal rat brain than maternal
hypothyroxinemia.
There is increasing evidence that the ontogenically pro-
grammed expression of D2 and D3, and the responses of
these enzyme activities to thyroid hormone deficiency or
excess, are the main mechanisms involved in the attainment
of adequate concentrations of T3 in different cerebral struc-
tures at different stages of development (54, 55), despite the
fact that at each time point the circulating concentration of T3
reaching all tissues is the same. This seems to be a general
principle during development, even for other tissues and
species (56–58). There is also an increasing consensus that an
excess of thyroid hormones, especially T3, may have adverse
effects on the developing fetus and that throughout gestation
the maternal-fetal unit has numerous mechanisms to avoid
this. This would explain the high expression and activities of
D3 in many structures of the maternal-fetal unit (58–62),
especially the uterus and placenta (63). Sulfation of the io-
dothyronines, their deiodination, and further desulfation by
sulfatases also seem to be playing important roles in tailoring
the amounts of T3 to changing temporal and spatial require-
ments during development (64, 65).
The abundant information obtained in pregnant sheep and
newborn lambs has been reviewed by others (64, 66–69).
Most of the available information has been obtained after
midgestation, corresponding to late fetal and early neonatal
brain development in man, and it supports the existence of
numerous mechanisms that would regulate the amounts of
circulating thyroid hormone in the fetus and newborn (69–
71). In this species, placentation is epitheliochorial, quite
different from that of man and of the rat. Despite this, limited
transfer does exist in this species, as shown by the presence,
before onset of FTF, of T3 in the fetal brain, some of which
is bound to the nuclear TR (72, 73). As in the rat, the hypo-
thyroxinemia of iodine-deficient ewes before midgestation is
accompanied by a reduced brain weight and changes in fetal
brain morphology (68).
In summary, experimental findings, mostly obtained in
the rat, provide an explanation for the lack of major irre-
versible brain damage at birth in the case of a human CH
fetus from a normal mother. They also explain the early
irreversible damage caused by ID, when both the mother and
fetus are hypothyroxinemic throughout gestation (74–76), as
well as the mechanisms involved in the preferential protec-
tive role, for the fetal brain, of T4 over T3.
Information obtained in man. Although man has an hemocho-
rial placenta similar to that of the rat, transfer of thyroid
hormones from mother to embryo and fetus may be quite
different in both species. However, there are many findings
that suggest that conclusions derived from experiments in
the rat may be relevant to our understanding of early human
brain development. These similarities are in Table 3.
Mechanisms preventing excessive amounts of thyroid hor-
mones from reaching the fetal circulation are also operative
in the human maternal-fetal unit. They involve both deio-
dinating enzymes, sulfotransferases, and sulfatases (64,
65,115–120.). Despite these mechanisms, maternal iodothy-
ronines do reach the fetus. Thyroid hormones, specifically T4,
are already available to embryonic and fetal tissues before
the onset of FTF (defined as the onset of secretion of the
iodothyronines by the fetal thyroid). In man this occurs at
midgestation (;18–22 weeks), coinciding with the develop-
ment of the pituitary-portal vascular system. T4 is found in
first trimester coelomic fluid, which bathes the yolk sac, from
the earliest date studied, namely at 6 weeks gestational age,
in concentrations that correlate significantly with maternal
circulating levels (83), whereas T3 is barely detectable. Al-
though coelomic fluid T4 concentrations are low compared
with those in adult blood, the FT4 concentrations are com-
parable with those that are biologically effective in adults
(84). T3 has been quantified in purified extracts from human
fetal brain as early as 9–10 weeks gestation (93, 94), and by
midgestation the concentration of T3 in the fetal brain reaches
34% of adult values and is, therefore, much higher than the level
previously inferred from the very low circulating fetal T3 [,10%
of adult values (121)]. This cerebral T3 is likely to have been
generated locally from coelomic fluid T4 of maternal origin.
Brain D2 and D3 may already have important roles in the
human fetal cortex before midgestation, with enzyme activities
responding to maternal hypothyroxinemia (98).
Nuclear TRs are present in the brain of 10-week-old fe-
tuses, increasing rapidly by 16 weeks, a period of very active
cortical neurogenesis (93, 94). TR occupancy by T3 was 25%
throughout this period (94). As a result, the number of T3-
occupied TR units in the whole fetal brain increases about
500-fold between 10 and 18 weeks, a finding that confirms
that maternal thyroid hormone does reach the human brain
early in gestation. It has later been found that TRs are already
expressed by 8 weeks of gestation, with ontogenic changes
specific for brain regions and receptor isoforms (95).
As in the rat, maternal to fetal transfer of thyroid hormones
continues until birth. Early evidence of this, following ad-
ministration of radiolabeled or stable iodothyronines, was
confirmed by Vulsma et al. (110). They showed that cord
blood T4 levels in newborns with a total organification defect
were not negligible, with values that were 20–50% of those
of normal newborns. This T4 had to be of maternal origin
because children with this congenital defect are unable to
synthesize thyroid hormones. If data obtained in the rat can
be extrapolated to man, this amount of T4 in the fetal circu-
lation ought to protect the brain of the CH fetus from T3
deficiency until birth (103), although signs of thyroid hor-
mone deficiency might be apparent in other tissues that are
more dependent on systemic T3 (i.e. delayed skeletal matu-
ration, lung maturation, etc.).
Thus, all the conditions that in adults are known to result
in biological effects of thyroid hormone are found in the
human fetal brain, namely functioning D2, a maternal
and/or fetal source of its substrate (T4), and specific nuclear
receptors partially occupied by the T3 generated from T4.
There is still very little information that might identify an
early biological effect resulting directly from this T3-TR in-
teraction in vivo. A recent study performed in vitro with organ
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cultures from 13- to 23-week human brains reports that the
addition of T3 stimulates cytoskeletal proteins, preferentially
actin (101), but it remains to be shown that a deficiency of
thyroid hormones in vivo would affect this process and do so
during the first trimester. Until a cerebral end point of thy-
roid hormone action early in development is characterized,
the long-lasting dispute concerning the mechanism(s) by
which maternal hypothyroxinemia would negatively affect
the fetal brain remains unresolved. Usually considered the
most likely possibilities are: 1) poor placental function and
maternal adaptation to pregnancy; 2) low levels of FT4 avail-
able to the first trimester embryonic tissues; or 3) both. In our
opinion, the evidence that is accumulating points to possi-
bility 3, with a major role for 2. A major role for possibility
1 would not explain the marked neurodevelopmental dam-
age of the neurological cretins whose mothers usually have
normal circulating T3 and are not clinically hypothyroid.
A unifying hypothesis for the findings summarized in
Tables 1–3
Whichever mechanism(s) is involved, epidemiological
and experimental studies strongly support that, inasmuch as
it may affect the availability of T4 (and consequently of T3)
to the developing brain, the main factor relating maternal
thyroid function to poor neurodevelopmental outcome of the
progeny is her hypothyroxinemia early in gestation, whether
or not TSH is increased. Fine regulation of the amounts of T3
ultimately generated from T4 by different mechanisms
would then tailor the availability of T3 to temporal and spa-
tial needs for thyroid hormone action in different brain struc-
tures, independently of circulating maternal or fetal T3. These
mechanisms, however, can only operate successfully when
there is enough substrate, namely T4. Persistence of maternal
hypothyroxinemia later in pregnancy, when coupled to con-
ditions that affect the capacity of the fetal thyroid to secrete
sufficient T4, and thus further decrease the availability of T4
to the brain, would aggravate the neurodevelopmental dam-
age. Figure 1 shows the proposed timing of insults to the
developing brain in these conditions, as well as in CH and
prematurity.
Severity and frequency of neurodevelopmental problems in the
offspring of hypothyroxinemic, compared with hypothyroid, women.
Table 4 attempts to quantify the magnitude of the cognitive
FIG. 1. Approximate timing of major insults to the brain resulting from hypothyroxinemia, superimposed on major neurodevelopmental events.
Conditions resulting in early maternal hypothyroxinemia, combined to later impairment of the fetal thyroid, are the most damaging, with central
nervous system (CNS) damage that is irreversible at birth. The most frequent cause is maternal ID and the presence of maternal AITDs. Unless
ID is also present, the CNS damage in congenital hypothyroidism is preventable by early postnatal treatment because the normal maternal
thyroxinemia has avoided damage to the brain until birth. If maternal hypothyroxinemia persists, normal maternal concentrations of T3 do
not protect the fetal brain because of its dependence on intracerebral regulation of local T3 availability by deiodinating pathways using T4 as
a substrate. Interruption of the contribution of maternal T4 in premature infants with an immature thyroid may also underlie their increased
risk of neurodevelopmental problems, the more severe the earlier their birth. The question mark indicates that we do not know whether very
early CNS development, corresponding to a period when the general morphogenesis of the pros encephalon (neurolation and segmentation) is
being determined, is thyroid hormone sensitive or not.
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limitation of the children born from mothers with inadequate
T4, FT4, TSH, or anti-TBO antibody titers during pregnancy, as
assessed from data provided by the authors of the different
studies, or from our calculations, using statistics reported in the
studies or provided by personal communication (Dr. V. Pop).
We have “normalized” the IQ scores given in different studies
to those of the test norm, taken as 100 6 15, to calculate the
frequency of children with IQ scores less than or equal to 85
(mean-1 sd; feeble-minded or mentally defectives) or less than
or equal to 70 (mean-2 sd; mentally retarded). Most studies
provide information regarding the frequency of neurodevel-
opmental scores that are less than or equal to 85, but only a few
indicate separately the frequency of those less than or equal to
70. The metanalysis of results from studies in iodine-deficient
areas do not include cretins, but only the apparently “normal”
population. All of the studies have applied corrections for likely
confounding factors.
The largest effects, as assessed from the loss of IQ points
in children from the untreated selected pregnant women (vs.
their controls) and from the corresponding odds ratios, are
associated with the use of ID (Study I), low first trimester FT4
(Study IV), and positivity of anti-TPO antibodies during
pregnancy (Study III) as criteria for selection of the women.
Although data from the study by Haddow et al. (1), using
second trimester elevated TSH values for the selection, do not
at first seem to be far behind, results summarized in Table 5
show an important difference with respect to Studies I-IV,
namely, the 5- to 7-fold smaller number of children at risk
who are, thus, identified. This is related to the lower fre-
quency with which an increased second trimester TSH is
found in pregnant women, compared with the frequency
with which women are selected using the other criteria: ID,
low maternal T4 or FT4, and/or autoimmune thyroid disor-
ders. Table 5 also highlights another important issue; al-
though the mean decreases in IQ points referred in the dif-
ferent studies are less severe than previously reported for
inadequately treated CH babies (30), the number of poten-
tially affected children might be 150–200 times greater.
Therefore, we do not fully agree with the proposal that
screening on the basis of an elevated TSH (1, 44) would be
the most adequate procedure to identify pregnant women at
risk of bearing children with neurodevelopmental problems
related to an inadequate maternal thyroid hormone status.
Even the determination of TSH during the first trimester
might not be adequate, because the maternal thyroid is then
affected by the TSH-like activity of the high levels of hCG and
first trimester TSH responses may be blunted (125). More-
over, some pregnant women with increased TSH might have
normal FT4 levels, and their inclusion in the study group may
affect the differences found between the neurodevelopmen-
tal outcome of the children from this group and that of the
control children. The same might occur if the control group
includes women with normal TSH, but who might have a
low first trimester FT4 (126). High maternal anti-TPO anti-
bodies, also related to poorer neuropsychological develop-
ment of the child, are not necessarily accompanied by ele-
vated maternal circulating TSH (23). The findings briefly
summarized above from premature hypothyroxinemic ba-
bies also indicate that they would not be detected using a
neonatal increase in circulating TSH as selection criterion.T
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Thus, we conclude that present information permits an
answer regarding points 1 and 2 of the aim of the present
comments, and we, therefore, suggest that the very pertinent
question asked by Utiger (44) regarding the frequency of
hypothyroidism in pregnant women ought to be modified
and referred to the frequency of first trimester maternal
hypothyroxinemia.
An even more important reason for our present comments
is that the major cause of maternal hypothyroxinemia world-
wide is ID, as clearly stressed by Utiger (44) in his recent
editorial accompanying the paper by Haddow et al. (1). Con-
trary to the usual findings in patients with primary hypo-
thyroidism, low circulating T4 levels are not necessarily ac-
companied by elevated TSH in situations of ID, especially if
it is mild or moderate. The thyroid gland is able to maintain
euthyroidism by responding to ID through intrathyroidal
autoregulatory mechanisms that do not require an increased
circulating TSH, such as an increased thyroidal blood-flow
and thyroid volume, increased thyroidal iodine clearance,
and preferential thyroidal synthesis and secretion of T3 over
T4, and increased intrathyroidal half-life of iodine-containing
compounds. Circulating T4 decreases and serum thyroglob-
ulin (Tg) increases, but TSH is usually normal both in
goitrous and nongoitrous subjects (127), very probably be-
cause circulating T3 is normal or elevated. Enlargement of the
thyroid and increased circulating Tg are more reliable pa-
rameters of ID than increased TSH (128). Even in areas of
very severe ID, where neurological cretins were born, TSH
levels (if increased), were not as high as in clinically hypo-
thyroid patients from iodine-sufficient areas (129, 130) and
were not related to the developmental outcome of the child
(15).
The frequency of maternal hypothyroxinemia is likely to
be much higher in areas of ID. In areas of grade III (severe)
ID, 43% of the pregnant women had a low PBI (,6 mg/dL),
with the protein-bound iodine values being positively cor-
related with neurodevelopmental outcome. Even in more
developed countries, the frequency of maternal first trimes-
ter hypothyroxinemia may be higher than in Holland where
Pop et al. (3) carried out their study, because of lower iodine
intakes. Thus, in the very thorough studies performed by
Glinoer at al (125) in Brussels, where ID is moderate (grade
II; median urinary I in pregnant women being 56 mg/L), up
to 30% of the women had low first trimester FT4 concentra-
tions, which is almost 10 times the frequency of elevated TSH
(2.3%) and 6 times the frequency of high titers of thyroid
autoantibodies (5.2%). In Madrid (131), where ID is milder
than in Brussels (the median urinary I being 90 mg/L
throughout pregnancy), the number of women with first
trimester FT4 levels that are less than the 10th percentile
values for women receiving an adequate iodine supplement
was increased 2-fold, again mostly without an increase in
circulating TSH more than or equal to the 98th percentile, or
an increase of women with positive thyroid autoantibodies.
The median urinary I of these supplemented women was 190
mg/L, which would correspond to a daily 24-h excretion of
270 mg I, provided we assume a mean diuresis of l.4 l. Al-
though their FT4 decreased during pregnancy, as repeatedly
reported by others (125), it was significantly higher, through-
out gestation, than that of the women who did not receive the
I supplement. Indeed, in each trimester FT4 was significantly
correlated with the urinary I, independently of gestational
week or T4-binding globulin concentrations. None of the
women on I supplements had goiter at delivery, in contrast
to 24% of those not receiving them. This information would
suggest that the iodine requirements of the pregnant woman
are 200–300 mg per day, at least in areas where the previous
borderline ID has not permitted the accumulation of iodine
stores sufficient to face her increased needs and those of the
fetus. These amounts are almost double those recommended
for children and for nonpregnant or nonlactating adults.
The studies from Brussels and Madrid suggest that these
women are likely to be hypothyroxinemic during pregnancy,
unless given iodine supplements from the onset or before (44,
132, 133). As pointed out by Utiger (44), the United States
might also be facing more problems related to ID than pre-
viously realized. His comment is based on the recent study
regarding iodine nutrition in the United States (134), which
has decreased markedly during the last 20 yr: the median
urinary I has decreased from 320 mg/L to 145 mg/L. As many
as 15% of women of childbearing age had concentrations
below 50 mg/L. North Americans are, therefore, also in-
cluded in the recommendation that iodine supplements be
taken during pregnancy, from the very beginning, or even
better, before its onset (44).
Moreover, as already discussed, ID does not necessarily
cause hypothyroidism with increased TSH and may not be
detected using an elevated TSH as criterion for selection of
pregnant women with increased risk of progeny with neu-
rodevelopmental deficits. Nonetheless, it may result in de-
TABLE 5. Comparison of the estimated frequencies of newborns with CH with those of children with impaired psychomotor development,
born to women with alterations of thyroid hormone status during pregnancy, detected using different criteria for selection. For these
calculations, we have used data reported in different studies (references in parentheses) and data shown in Table 4
Study CH I II III IV V
Criteria for selection TSH of newborn
high, and/or T4 low
Severe ID area Low BEI Anti-TPO 1
during pregnancy
1st trimester FT4
#10th percentile
2nd trimester TSH
.98th percentile
% of pregnant women selected
(not treated)
All? 9.4% (17) 8% (21) 10% (22) 2.5% (1, 126)
% of newborns at risk 0.025–0.030% 46% 1.3–3.1% 2.5% 5% 0.47%
Frequency of progeny with IQ
#85a
1:3000–1:4000 1:2 1:32–1:76 1:39 1:30 1:150
Frequency of progeny with IQ
#70
1:7 1:150 1:250
a Includes all children with IQ #85, without subtracting those with IQ #70.
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creased maternal FT4 in a relatively large number of women
and to the ensuing increased risk of psychomotor defects (3).
That this relative ID is so easily preventable, and at such a
small cost, makes it all the more frustrating that the general
public and the medical community are not fully aware of the
problems that ID may continue to pose for future
generations.
Although our present comments have been focused
mainly on the relationship between inadequate maternal
thyroid function, especially hypothyroxinemia, and neuro-
developmental problems of her child, other negative effects
cannot be overlooked, such as an increased rate of sponta-
neous abortions, placental disruptions, fetal distress, mal-
formations, prematurity, decreased birth weight, poorer
perinatal outcome, and pregnancy-induced hypertension
(20, 22, 26, 27, 135–138). Those caused by autoimmune thy-
roid disorders (AITDs) have been extensively studied and
reviewed by Glinoer (4, 125, 139), both with respect to sub-
clinical and overt hypothyroidism and to subclinical and
overt hyperthyroidism and transient gestational hyperthy-
roidism. His conclusion is that systematic screening for au-
toimmune disorders and for TSH more than 4 or less than 0.1
mU/mL early in pregnancy is justified by present evidence,
considering both their frequency and the increased risk of
adverse pregnancy outcome and perinatal morbidity, and
the benefits for the child and for the future health of the
mother of adequate treatment. We should again like to re-
mark that this conclusion was already reached by Glinoer (4,
125, 139) without taking into account that high titers of ma-
ternal anti-TPO antibodies during pregnancy are also a
marker of impaired neuropsychological development of the
child (23), or that the latter outcome is very poor in the
progeny of untreated mothers with high titers of TSH re-
ceptor blocking antibodies (35, 140, 141).
To screen or not to screen, that is the question. Presently available
epidemiological and experimental evidence strongly sup-
ports the need for an increasing widespread attention to
maternal thyroid status during pregnancy. Glinoer (125, 139)
has already proposed systematic screening algorithms (4) for
AITDs and subclinical and overt hypo- and hyperthyroidism
early in pregnancy, as well as the ensuing treatment proto-
cols. The proposed screening program is based on the de-
termination of positive anti-TPO antibodies (also positive
anti-Tg antibodies if economically feasible) and TSH more
than 4 or less than 0.1 mU/mL, preferably at 12 weeks of
gestation. These algorithms do not include tests for TSH
receptor blocking antibodies, despite the high risk of the very
severe neurodevelopmental damage to the offspring, possi-
bly because of their low incidence [1:180 000 pregnancies
(142)] and because the bioassays developed so far are not
easily performed. In view of the evidence we have reviewed
here, however, which shows a relationship between early
maternal hypothyroxinemia and poor neurodevelopmental
outcome, we believe that inclusion of screening for low FT4
as well would considerably increase the benefits of the pro-
gram proposed by Glinoer (4).
The cut-off points of the FT4 values needed to establish the
degree of hypothyroxinemia at different gestational ages
(and using different commercially available kits) remains to
be defined, ensuring it is done in pregnant women with a
confirmed iodine intake of 200–300 mg/day (145–220 mg I/L
urine) or more. Inclusion in the reference group of women on
an insufficient iodine intake would underestimate the lowest
10th percentile.
How to correct the hypothyroxinemia in time to avoid
neurodevelopmental problems might also require further
controlled studies or screening trials, as stressed in a recent
editorial by Pop et al. (123). However, despite the different
methodologies and study designs used in the studies per-
formed by Man and Serunian (20, 21) and by Pop et al. (3) in
women who were reportedly iodine sufficient (from Rhode
Island and The Netherlands), there are some striking simi-
larities in the IQ scores of their children, and the frequency
of values less than or equal to 85. But, only the studies from
Man and Serunian (20, 21) included a group of women whose
low BEI was promptly corrected by treatment with thyroid
extracts. It is interesting that none of the children born from
these mothers had IQ scores less than or equal to 85, and the
mean IQ was actually higher than that of the progeny of
women without hypothyroxinemia, strongly suggesting that
treatment would be effective.
A clear definition of the cut-off values of the proposed
screening tests and the most appropriate treatment of pos-
itive cases were also lacking when neonatal thyroid screen-
ing programs were started: despite that they have become a
clear example of success in the prevention of mental retar-
dation. The proposed biochemical markers are all presently
available as blood spot tests (143). Thus, linking thyroid
screening of pregnant women to the logistic facilities devel-
oped for local neonatal thyroid screening programs might
considerably improve the cost to benefit ratio, because the
biochemical tests per se do not constitute the major expense
of such programs.
Glinoer’s proposal (4) for screening at 12 weeks of gesta-
tion seems reasonable for hypothyroxinemia as well, because
an earlier first prenatal visit is highly unlikely. Blood samples
would then be taken for the determination of FT4, anti-TPO
(and possibly anti-Tg) antibodies, and for TSH. Women who
were not screened during this period should still be tested
later in gestation because potential benefits might still be
obtained, especially if the condition is caused by an auto-
immune disorder that may also affect the fetal thyroid.
Screening before pregnancy would probably benefit those
women presenting with high antibody titers, abnormal val-
ues of TSH, or hypothyroxinemia, but may well be insuffi-
cient: pregnancy itself may be the factor that contributes to
an inadequate availability of T4 for the fetus, unmasking an
underlying thyroid failure, or an iodine intake insufficient to
meet the increased maternal and fetal needs.
For the future assessment of the results of the inclusion of
FT4 in the screening program, it would be important to eval-
uate the iodine intake of the pregnant woman by determin-
ing iodine and creatinine in casual urine samples taken on the
same day as the blood samples. An inexpensive method for
the determination of urinary iodine, easy to perform and not
requiring costly hardware, is presently available, making
these determinations easy to incorporate into any biochem-
ical clinical laboratory or neonatal thyroid screening pro-
gram (144). We are currently attempting to develop a method
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for the determination of iodine in urine spots on filter paper.
These data would later disclose the proportion of women
from different regions in whom hypothyroxinemia is related
to ID and, therefore, easily prevented or corrected without
further treatments.
At this first prenatal visit, all pregnant women would
immediately start supplementing their usual diet, through-
out pregnancy and lactation, with 200–300 mg I/day, either
in the form of KI or KIO3 tablets or vitamin-mineral mixtures
(44, 145). Even if the urinary iodine excretion value later
indicates that the iodine intake was already adequate for
pregnancy, the supplementation would not harm. It has,
indeed, been shown that the administration of much larger
amounts of iodine during any stage of pregnancy, such as
those delivered by ingestion or injection of iodized oils, does
not harm fetal neurodevelopment (146, 147). If the TSH data
at screening suggest thyroid hyper function, supplementa-
tion could be stopped. Inclusion of iodine supplementation
into the program is likely to be much more effective in en-
suring permanent correction of maternal iodine deficiency
than mere information programs to the general public and
the medical profession.
If the results of the screening tests indicate abnormal val-
ues of either thyroid autoantibodies, TSH, or both, the al-
gorithms outlined by Glinoer (4) could be implemented. If
the only abnormal value is a FT4 that is low for gestational
week, a new blood sample would be withdrawn within 2
weeks for the determination of serum FT4. Correction, or
amelioration, of the FT4 levels would suggest that supple-
mentation of the diet with iodine is sufficient. If, despite
iodine supplementation, FT4 remains persistently lower than
the 10th percentile value for normal pregnant women with
a confirmed adequate iodine intake at comparable weeks of
gestation, additional treatment with T4 might be considered
pertinent to ensure the FT4 levels that have been found to be
normal in iodine-sufficient women at the same stage of
pregnancy.
Summary. Screening programs for the identification of preg-
nant women with hypothyroxinemia, hypothyroidism,
AITDs, or hyperthyroidism are likely to pose more organi-
zational problems than the screening of neonates for CH.
However, the much greater frequency with which alterations
of maternal thyroid function are detected, which potentially
jeopardize the outcome of pregnancy and increase the risk of
neurodevelopmental impairment of the offspring, ought to
encourage their implementation. Fukushi et al. (143) have
recently reported that a screening program of the thyroid
function of pregnant women from the Sapporo region in
Japan was initiated in 1991, and data are available for 70,632
women. The authors conclude it is a useful program, despite
the fact that thyroid disease among pregnant women is likely
to be lower in Japan than in other countries (hypothyrox-
inemia due to ID is highly unlikely). These programs are
likely to greatly increase the awareness of the general med-
ical profession of the importance of the prevention of ID
during pregnancy and also lead to a much needed closer
collaboration between gynecologists and endocrinologists
for adequate treatments following well-defined protocols
(2, 4).
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